Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Active surveillance

12 evidence topics · 12 sources

Pooled analysis of three prospective observational studies: treatment-free survival and progression

“In this pooled analysis from three prospective observational studies on patients with extra-abdominal desmoid-type fibromatosis, we confirm that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients (n = 282) with a median follow-up of 53 months (IQR, 39–63) were included. The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The 3- and 5-year PFS rates (95% CI) were 54% (48%–60%) and 51% (45%–58%), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In total, 93 of 282 (33.0%) patients received AT after initial AS, of which 45 (48.4%) patients received AT after RECIST progression, and 48 (54.6%) patients received AT after symptomatic progression alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

GRAFITI prospective cohort study of non-intraabdominal tumors

“In this multicenter prospective cohort study (NTR4714), adult patients with non-intraabdominal DTF were followed during an initial AS approach for 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 105 patients started with AS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At 3 years, cumulative incidence of the start of active treatment was 30% (95% confidence interval [CI] 21–39) and PFS was 58% (95% CI 49–69). Median time to start active treatment and PFS were not reached at a median follow-up of 33.7 months. During AS, 32% of patients had stable disease, 28% regressed, and 40% demonstrated initial progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Larger tumor size (≥5 cm; hazard ratio = 2.38 [95% CI 1.15–4.90]) and S45F mutation (hazard ratio = 6.24 [95% CI 1.92–20.30]) were associated with the start of active treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The follow-up protocol of the GRAFITI trial consisted of follow-up visits and imaging examinations (Ultrasound [US] and MRI) at baseline, 3,6,9,12,18,24, and 36 months (window ±3 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote